Streetbeat News

CHRO

Chromocell Therapeutics Corporation

https://chromocell.com

Industry

Biotechnology

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Open

0.69

Mkt cap

3.6M

Volume

13K

High

0.69

P/E Ratio

-0.38

52-wk high

6.00

Low

0.63

Div yield

N/A

52-wk low

0.52

Chromocell Therapeutics Corporation has announced its new injectable depot program using peripheral nerve blocks for post-operative pain treatment. This program is based on their NaV1.7 molecule and targets a significant market in knee and shoulder surgeries.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:33 pm

Chromocell Therapeutics shares rose following the announcement of an increase in their share repurchase plan by an additional $500K, bringing the total to $750K.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:49 pm

Chromocell Therapeutics Corporation (NYSE:CHRO) has amended its stock repurchase plan, increasing the total value of shares available for repurchase by $500,000 to $750,000. The termination date of the plan has been extended to June 30, 2025.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:48 pm

Several health care stocks experienced significant price movements during Friday's intraday session. Notable gainers included Catheter Precision (AMEX:VTAK) with a 142.8% increase, and Tevogen Bio Holdings (NASDAQ:TVGN) with a 49.28% rise. On the losing side, NKGen Biotech (NASDAQ:NKGN) fell by 31.9%, and Orgenesis (NASDAQ:ORGS) declined by 28.05%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 4:31 pm

In Friday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Catheter Precision (AMEX:VTAK) with a 151.9% increase, Akanda (NASDAQ:AKAN) up 71.13%, and Tenon Medical (NASDAQ:TNON) rising 39.06%. On the losing side, Orgenesis (NASDAQ:ORGS) fell 37.9%, Molecular Templates (NASDAQ:MTEM) dropped 30.11%, and NKGen Biotech (NASDAQ:NKGN) decreased by 29.02%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 12:09 pm

In Wednesday's after-market session, several health care stocks experienced significant price movements. Molecular Templates (MTEM) saw a remarkable increase of 189.2%, while HCW Biologics (HCWB) experienced a notable decline of 14.8%. Other gainers included Klotho Neurosciences (KLTO) and Chromocell Therapeutics (CHRO), while Biodexa Pharmaceuticals (BDRX) and Capricor Therapeutics (CAPR) were among the losers.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 8:31 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Prenetics Global, Chromocell Therapeutics, Nuwellis, MiNK Therapeutics, Accolade, and Tharimmune saw gains, while Trevena, Entero Therapeutics, NKGen Biotech, Kazia Therapeutics, Carmell, and Silexion Therapeutics experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:31 pm

Several healthcare stocks experienced significant price movements in Friday's pre-market session. Mural Oncology, Universe Pharmaceuticals, Biodesix, Allakos, SCWorx, and aTyr Pharma saw notable gains, while Avinger, Renovaro, Sage Therapeutics, Chromocell Therapeutics, Reshape Lifesciences, and BioCardia experienced declines.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 12:07 pm

The article highlights the pre-market movements of various healthcare stocks on Tuesday. Notable gainers include Silexion Therapeutics, Adagio Medical Holdings, and Chromocell Therapeutics, while significant losers include Shattuck Labs, IGM Biosciences, and Applied DNA Sciences.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 12:07 pm

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Cardio Diagnostics Holdings, TC BioPharm, and Seres Therapeutics, while Cue Biopharma and enVVeno Medical were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.